Cambridge Nutritional Sciences (LSE:CNSL) is working to rebuild momentum after full-year results showed a 16% fall in revenue, a swing to an adjusted operating loss and a sizeable goodwill write-down. The diagnostics specialist, whose results for the year to 31 March 2026 were published on 8 September 2026, has restructured its UK operations and refreshed its sales leadership, and is now asking shareholders to look past geopolitical disruption in several export markets towards an improving margin profile and a long-running regulatory upgrade programme.

What the company does

The group is a specialist medical diagnostics business focused on food sensitivity and nutrition testing. Its main product lines are FoodPrint, its largest category, the Food Detective rapid test and CNSLab laboratory testing services. It sells in the UK, India, the Americas, Europe, Africa, the Middle East and Asia, both directly and through distributors, and recently signed a new five-year agreement with a UK white-label partner.

Latest developments

Revenue for the year fell to £7.0 million from £8.3 million. A trading update in April 2026 had attributed much of the shortfall to reduced and delayed orders from the Middle East and Asia in the second half, linked to geopolitical instability. In the final results, FoodPrint sales fell 12% to £4.3 million and Food Detective dropped 46% to £1.0 million, while CNSLab services rose 2% to £1.7 million. UK revenue held steady and India grew by 23% in sterling terms, but the Americas, Africa and the Middle East, and Asia all recorded declines.

Management has taken action on costs and structure. A UK restructuring completed in March 2026 reduced headcount from 76 to 58, and the board accepted a voluntary 10% salary cut. A customer success team was created, a regional sales manager joined in April and a new global sales director was appointed in June.

Financial picture

Gross margin improved to 67.8% from 65.3%, helped by production yields rising to 64.7% from 52.3%. Even so, adjusted EBITDA moved from a £0.4 million profit to a £0.4 million loss. The statutory loss after tax was £5.8 million, including a £3.0 million goodwill impairment and the derecognition of a £1.4 million deferred tax asset. A £0.3 million bad debt provision related to an Americas distributor.

Cash and deposits fell to £2.6 million from £4.9 million, reflecting operating outflows and capital investment, although the company had no short-term borrowings at the year end. The directors adopted the going concern basis through to March 2028 and said a reverse stress test showed resources would last even under a further significant deterioration in sales and margins. No dividend was declared.

Sector and index context

As one of the smaller healthcare constituents of the FTSE AIM All Share Index, Cambridge Nutritional Sciences operates in a niche corner of in-vitro diagnostics. The sector faces tightening European regulation under the In Vitro Diagnostic Regulation, which raises compliance costs but can also create barriers to entry for companies that complete the process.

Key risks

The business remains exposed to geopolitical disruption in export markets, distributor credit risk and longer sales cycles for new customers, which the company flagged in November 2025. The cost and timing of its IVDR programme, expected to make progress through 2027, is another consideration, as is the shrinking cash balance.

What to watch next

Investors will look for evidence that restructuring savings are coming through in the current financial year, as management expects, and for a recovery in orders from the Middle East and Asia. The interim results for the six months to September 2026, along with updates on IVDR progress and the new sales team's impact, are likely to be the next key markers.